Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
出版年份 2013 全文链接
标题
Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy
作者
关键词
-
出版物
Cancers
Volume 5, Issue 4, Pages 64-91
出版商
MDPI AG
发表日期
2013-01-21
DOI
10.3390/cancers5010064
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase II study of cetuximab (Cetuximab) with cisplatin and capecitabine (Xeloda) as 1st line treatment in advanced gastric cancer
- (2017) X. Zhang et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II trial of docetaxel, cisplatin, irinotecan, and bevacizumab in metastatic esophagogastric cancer
- (2017) P. C. Enzinger et al. JOURNAL OF CLINICAL ONCOLOGY
- ATTAX2: Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophago-gastric cancer—Final results of a multicentre phase II trial by the AGITG
- (2017) N. C. Tebbutt et al. JOURNAL OF CLINICAL ONCOLOGY
- Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer: First results of a multicenter phase II trial (AGMT Gastric- 2
- (2017) E. Woell et al. JOURNAL OF CLINICAL ONCOLOGY
- C-met as a therapeutic target for metastatic potential of gastric cancer.
- (2017) H. Cho et al. JOURNAL OF CLINICAL ONCOLOGY
- CALGB 80403/ECOG 1206: A randomized phase II study of three standard chemotherapy regimens (ECF, IC, FOLFOX) plus cetuximab in metastatic esophageal and GE junction cancer.
- (2017) P. C. Enzinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Final results of a phase II study of modified FOLFOX6 (mFOLFOX6) and erlotinib (E) in patients with metastatic adenocarcinoma of the esophagus (Eso) and gastroesophageal junction (GEJ).
- (2017) Z. A. Wainberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim safety analysis from TYTAN: A phase III Asian study of lapatinib in combination with paclitaxel as second-line therapy in gastric cancer.
- (2017) T. Satoh et al. JOURNAL OF CLINICAL ONCOLOGY
- Lapatinib in combination with ECF/x in EGFR1 or HER2-overexpressing first-line metastatic gastric cancer (GC): A phase II randomized placebo controlled trial (EORTC 40071).
- (2017) A. Roth et al. JOURNAL OF CLINICAL ONCOLOGY
- AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).
- (2017) Y. Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival analysis by pooling risk factors in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo (pla) in patients (pts) with advanced gastric cancer (AGC).
- (2017) Y. Kang et al. JOURNAL OF CLINICAL ONCOLOGY
- REAL3: A multicenter randomized phase II/III trial of epirubicin, oxaliplatin, and capecitabine (EOC) versus modified (m) EOC plus panitumumab (P) in advanced oesophagogastric (OG) cancer—Response rate (RR), toxicity, and molecular analysis from phase II.
- (2017) I. Chau et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized phase II study of nimotuzumab, an anti-EGFR antibody, plus irinotecan in patients with 5-fluorouracil–based regimen-refractory advanced or recurrent gastric cancer in Korea and Japan: Preliminary results.
- (2017) Y. H. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3).
- (2017) Tom Samuel Waddell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1.
- (2017) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel targeted agents for gastric cancer
- (2012) Lian Liu et al. Journal of Hematology & Oncology
- A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
- (2011) J. A. Chan et al. ANNALS OF ONCOLOGY
- Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer
- (2011) Taroh Satoh et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Molecularly targeted therapies in unresectable-metastatic gastric cancer. A systematic review
- (2011) Flora Zagouri et al. CANCER TREATMENT REVIEWS
- An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer
- (2011) M. Moehler et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting the human EGFR family in esophagogastric cancer
- (2011) Alicia Okines et al. Nature Reviews Clinical Oncology
- Anti-HER agents in gastric cancer: from bench to bedside
- (2011) Lorenzo Fornaro et al. Nature Reviews Gastroenterology & Hepatology
- c-MET as a potential therapeutic target and biomarker in cancer
- (2011) J. Rafael Sierra et al. Therapeutic Advances in Medical Oncology
- Critical appraisal of trastuzumab in treatment of advanced stomach cancer
- (2011) Judith Meza-Junco et al. Cancer Management and Research
- HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain
- (2011) E. U. Cidon et al. Journal of Oncology
- Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
- (2010) S. Rao et al. ANNALS OF ONCOLOGY
- A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers
- (2010) B. F. El-Rayes et al. ANNALS OF ONCOLOGY
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
- (2010) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors
- (2010) Matthew D. Galsky et al. INVESTIGATIONAL NEW DRUGS
- Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer
- (2010) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase II study of sunitinib as second-line treatment for advanced gastric cancer
- (2010) Yung-Jue Bang et al. INVESTIGATIONAL NEW DRUGS
- Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
- (2010) Alicia F.C. Okines et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
- (2010) Jennifer L. Spratlin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Sorafenib in Combination With Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: ECOG 5203
- (2010) Weijing Sun et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
- (2010) Toshihiko Doi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil With Bevacizumab in Patients With Metastatic Gastroesophageal Adenocarcinoma
- (2010) Manish A. Shah et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer
- (2010) Cristina P. Rodriguez et al. Journal of Thoracic Oncology
- Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)
- (2010) Philip J. Gold et al. Journal of Thoracic Oncology
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
- (2009) S-W Han et al. BRITISH JOURNAL OF CANCER
- Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
- (2009) C Pinto et al. BRITISH JOURNAL OF CANCER
- Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
- (2009) E. Martinelli et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Current status of cediranib: the rapid development of a novel anti-angiogenic therapy
- (2009) Colin R Lindsay et al. Future Oncology
- A prospective phase II study of cetuximab in combination with XELOX (capecitabine and oxaliplatin) in patients with metastatic and/or recurrent advanced gastric cancer
- (2009) Chul Kim et al. INVESTIGATIONAL NEW DRUGS
- Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer
- (2008) S Rao et al. BRITISH JOURNAL OF CANCER
- The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
- (2008) Jin Won Kim et al. CANCER LETTERS
- Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity
- (2008) Howard Safran et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started